Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 8/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30290030 | 1.00 | F12 (0.36) | F12BCHEALDH1A1MEN1GAA | |
| SCHEMBL2172225 | 1.00 | F12 (0.36) | F12BCHEALDH1A1MEN1GAA | |
| SCHEMBL224810 | 1.00 | F12 (0.36) | F12BCHEALDH1A1MEN1GAA | |
| Hydrochloric Acid SCHEMBL27979283 | 0.98 | ALDH1A1 (0.37) | F12BCHEALDH1A1MEN1GAA | |
| Ethane SCHEMBL11061598 | 0.96 | BCHE (0.36) | F12BCHEHTR2C | |
| SCHEMBL1652868 | 0.88 | BCHE (0.34) | F12BCHEALDH1A1MEN1GAA | |
| SCHEMBL793625 | 0.78 | CHRNB4 (0.37) | ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL29636531 | 0.78 | CHRNB4 (0.37) | ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL8703745 | 0.78 | CHRNB4 (0.37) | ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL12350365 | 0.75 | HTR2C (0.39) | F12BCHEALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1964925-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-1,2,3,4 -TETRAHYDROQUINOLINES | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-8754221-B2 | Optically active cyclic alcohol compound and method for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-17 | — | — | US | disclosed |
| EP-2727594-A1 | NOVEL PHARMACEUTICAL COMPOSITION | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20130237708-A1 | Optically Active Cyclic Alcohol Compound And Method For Preparing The Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-12 | — | — | US | disclosed |
| EP-2371820-B1 | Optically active cyclic alcohol compound and method for preparing the same | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-8471028-B2 | Optically active cyclic alcohol compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-1944291-B1 | Optically active cyclic alcohol compound and method for producing same | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-06-13 | — | — | EP | disclosed |
| EP-2371820-A1 | Optically active cyclic alcohol compound and method for preparing the same | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-20110196157-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION | 2011-08-11 | — | — | US | disclosed |
| US-7989627-B2 | Optically active cyclic alcohol compound and method for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7972836-B2 | Method of enzymatic optical resolution of racemic 4-hydroxy-1,2,3,4-tetrahydroquinoline | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100152451-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20090269821-A1 | Method for Preparing Optically Active 4-Hydroxy-1,2,3,4-Tetrahydroquinoline Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1964925-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-1,2,3,4 -TETRAHYDROQUINOLINES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-03 | — | — | EP | disclosed |
| EP-1944291-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PRODUCING SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196157-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME | ADH1C, ADH1A, ADH5 | F12 999/4885BCHE 489/4885ALDH1A1 25/4885 |
| US-20100152451-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME | ADH1C, ADH1A, ADH5 | F12 999/4885BCHE 489/4885ALDH1A1 25/4885 |
| US-20130237708-A1 | Optically Active Cyclic Alcohol Compound And Method For Preparing The Same | ADH1C, ADH1A, ADH5 | F12 999/4885BCHE 489/4885ALDH1A1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.